Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Tharimmune, Inc. - Common Stock
(NQ:
THAR
)
0.3274
UNCHANGED
Streaming Delayed Price
Updated: 3:59 PM EDT, May 23, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
3,194
Open
0.3274
Bid (Size)
0.3249 (40)
Ask (Size)
0.3276 (1)
Prev. Close
0.3274
Today's Range
0.3274 - 0.3274
52wk Range
0.1434 - 4.790
Shares Outstanding
N/A
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday
Today 7:16 EDT
We're diving into the biggest pre-market stock movers that traders need to know about on Friday morning with all of the latest news!
Via
InvestorPlace
Why Tharimmune (THAR) Shares Are Moving
May 22, 2024
Tharimmune shares are trading lower by 16.4% during Wednesday's session. The company announced a 1-for-15 reverse stock split.
Via
Benzinga
Performance
YTD
-35.16%
-35.16%
1 Month
-13.61%
-13.61%
3 Month
-13.61%
-13.61%
6 Month
-88.61%
-88.61%
1 Year
+48.75%
+48.75%
More News
Read More
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
May 22, 2024
Via
Benzinga
Tharimmune Announces 1-for-15 Reverse Stock Split
May 22, 2024
Via
ACCESSWIRE
THAR Stock Earnings: Tharimmune Reported Results for Q4 2023
May 09, 2024
Via
InvestorPlace
Tharimmune to Present at the Emerging Growth Conference on March 7, 2024
March 05, 2024
Via
ACCESSWIRE
Tharimmune Announces Positive Results in Phase 1 Clinical Trial of TH104, its Lead Clinical Therapeutic Candidate
February 20, 2024
Via
ACCESSWIRE
Tharimmune, Inc. (NASDAQ: THAR) Featured in Coverage of the EF Hutton Annual Global Conference
May 16, 2024
Via
Investor Brand Network
Tharimmune To Participate in Two Upcoming Investor Conferences in May
April 30, 2024
Via
ACCESSWIRE
Tharimmune Announces Option Agreement for Key Technologies for Generating HER2/HER3 Antibody Drug Conjugates (ADCs)
April 23, 2024
Via
ACCESSWIRE
Tharimmune Announces Scientific Advisory Board to Drive Clinical-Stage Lead in Chronic Liver Disease and Early-Stage Tunable Knob Domains for Generating Antibody Drug Conjugate (ADC) Biotherapeutics
April 15, 2024
Via
ACCESSWIRE
Tharimmune's Oral 'Under The Cheek' Candidate At Par With FDA-Approved Injectable With Potential For Chronic Liver Disease
February 20, 2024
Via
Benzinga
Tharimmune Announces Initiation of Phase 1 Clinical Trial of TH104 and Provides Business Update
January 29, 2024
Via
ACCESSWIRE
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
February 20, 2024
Via
Benzinga
Tharimmune Announces Dosing of First Patient in Phase 1 Clinical Trial of TH104, its Lead Candidate for Pruritus in Primary Biliary Cholangitis
February 05, 2024
Via
ACCESSWIRE
12 Health Care Stocks Moving In Thursday's After-Market Session
January 25, 2024
Via
Benzinga
12 Health Care Stocks Moving In Wednesday's After-Market Session
January 24, 2024
Via
Benzinga
Perspective Therapeutics And 3 Other Stocks Under $1 Insiders Are Buying
December 19, 2023
Via
Benzinga
Topics
Stocks
Exposures
US Equities
Tharimmune Announces Positive Topline Data with TH104, its Lead Candidate for Moderate-to-Severe Pruritus in Chronic Liver Disease Patients
December 11, 2023
Via
ACCESSWIRE
Why Hello Group Shares Are Trading Higher By Around 8%; Here Are 20 Stocks Moving Premarket
December 08, 2023
Via
Benzinga
12 Health Care Stocks Moving In Thursday's After-Market Session
December 07, 2023
Via
Benzinga
12 Health Care Stocks Moving In Monday's After-Market Session
December 04, 2023
Via
Benzinga
Tharimmune, Inc. Announces Closing of $11 Million Public Offering
November 30, 2023
Via
ACCESSWIRE
Stonegate Healthcare Partners Releases Report on Transformative Therapies for Pruritus Management
November 30, 2023
Via
Newsfile
BioMedNewsBreaks – Tharimmune Inc. (NASDAQ: THAR) Announces Pricing of $10M Public Offering
November 29, 2023
Via
Investor Brand Network
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.